Goa-based diagnostics company Molbio Diagnostics has filed a Draft Red Herring Prospectus (DRHP) with SEBI for its IPO. The company will launch a fresh issue of ₹200 crore and existing shareholders will sell approximately 1.25 crore equity shares through an Offer for Sale (OFS). This values the company at approximately ₹12,490 crore.
Molbio Diagnostics IPO: Molbio Diagnostics, a Point-of-Care Diagnostics company based in Goa, has filed draft papers with SEBI (Securities and Exchange Board of India) for its IPO (Initial Public Offering). The company will raise ₹200 crore through this public issue in fresh funding, while existing promoters and investors will sell 1.25 crore shares. The company recently announced a 4:1 bonus issue, which resulted in an adjusted issue price of ₹1,090 per share and a valuation of approximately ₹12,490.8 crore for the company.
How Many Shares Will Be in the Offer-For-Sale?
According to the draft papers, the company will sell a total of 1.25 crore equity shares in this IPO. Out of these, shares worth ₹200 crore will be newly issued, while the remaining portion will come through OFS. This means that existing shareholders and promoters are preparing to exit by selling a large portion of their stake.
Molbio Diagnostics' promoters, Exxora Trading LLP and Chandrasekhar Bhaskaran Nair, hold 46.65 percent stake in the company. These promoters will sell 29.12 lakh shares during the IPO. This clearly indicates that the promoters will also partially reduce their stake.
Role of Investors
Regarding investors, the company includes names such as V Sciences Investments, India Business Excellence Fund III, Gopalkrishna M Kini, Gopalakrishna Sampathgiri, J Guru Dutt, Sangeetha M Kini, and MA Usha Rani. These investors collectively hold a 53.35 percent stake. These investors will sell 96.44 lakh shares in the IPO. The largest shareholders are India Business Excellence Fund III and V-Sciences Investments, holding 12.66 percent and 8.93 percent stake respectively. Both these investors have been associated with the company since January 2021 and September 2022.
Company History
Molbio Diagnostics was founded in the year 2000. The company has carved a niche for itself in point-of-care diagnostic testing. Recently, there were some major transactions in the company. On July 14, 2025, Shruthi G Kini transferred 9,175 shares to Navin Mahavirprasad Dalmia. This deal was executed at ₹5,450 per share.
Bonus Issue and Valuation
The company announced a bonus issue in the ratio of 4:1 on July 29, 2025. This means that four new shares were issued for every one share held. After the bonus issue, the adjusted price of the company's share was fixed at ₹1,090 per share. Based on this, Molbio Diagnostics is valued at approximately ₹12,490.8 crore.
Use of Funds Raised from IPO
Although detailed information regarding the use of funds has not been disclosed in the DRHP, diagnostic sector companies generally resort to IPOs to expand their business, introduce new technologies, increase production capacity, and repay debt. It is expected that Molbio Diagnostics will also use the funds raised from the IPO in these areas.
Why This Company Is Special
Molbio Diagnostics is one of the select companies in India that has promoted point-of-care diagnostic testing in the healthcare sector. Through this technology, patients get immediate test reports, which allows treatment to begin quickly. The company's products are being used not only in India but also internationally. This is the reason why investors are eyeing this IPO.
As soon as Molbio Diagnostics filed the DRHP with SEBI, the market became abuzz with this IPO. Given the rapidly growing demand in the healthcare and diagnostics sector, analysts are considering it an attractive offer. Especially after Covid, the business model of diagnostics companies has become even ber.
Preparation for New Entry in the Stock Market
Molbio Diagnostics' IPO will be a major topic of discussion for investors in the coming months. Considering the company's current valuation and b business model, this offering may receive a good response in the market. Through the IPO, the company will register its presence in the stock market and investors will get an opportunity to participate in it.
